[An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
In a randomised blind study with 404 patients 1 capsule Etofibrate per day (500 mg) in sustained release dosage form was tested in comparison to other lipid-lowering drugs. The trial extended to eight weeks and was performed in eight clinics and in four practices for internal medicine. Serum-cholesterol and serum-triglycerides were controlled at the beginning and at the end of the observation period. The result was a significant decrease of the cholesterol-level up to 22% and a decrease of the triglyceride-level up to 43%. Also the patients pretreated with other drugs showed a furthermore improvement of the former therapy. Side effects were very rare and it was never necessary to stop the treatment.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
D003692:Delayed-Action Preparations; D000960:Hypolipidemic Agents; D014280:Triglycerides; C009746:etofibrate; D002995:Clofibric Acid; D002784:Cholesterol; D002994:Clofibrate
Alternative in der Therapie primärer Hyperlipidämien: Etofibrat in Retardform.